Acasti Pharma Files 8-K for Regulatory Disclosure

Ticker: GRCE · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1444192

Acasti Pharma INC. 8-K Filing Summary
FieldDetail
CompanyAcasti Pharma INC. (GRCE)
Form Type8-K
Filed DateApr 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: ACST

TL;DR

ACST filed a routine 8-K, no major news.

AI Summary

Acasti Pharma Inc. filed an 8-K on April 1, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Acasti Pharma Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not contain information that suggests an immediate change in risk for the company.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Acasti Pharma Inc.?

The primary purpose of this 8-K filing is to provide a Regulation FD Disclosure and to report Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on April 01, 2024.

What is the Commission File Number for Acasti Pharma Inc.?

The Commission File Number for Acasti Pharma Inc. is 001-35776.

What is the principal executive office address for Acasti Pharma Inc.?

The principal executive office address for Acasti Pharma Inc. is 103 Carnegie Center Suite 300, Princeton, New Jersey 08540.

Does this filing report any specific material events or financial results?

This filing does not detail specific material events or financial results beyond the standard reporting categories of Regulation FD Disclosure and Financial Statements and Exhibits.

Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-04-01 08:00:15

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The following information is furnished pursuant to Item 7.01 "Regulation FD Disclosure." On April 1, 2024, Acasti Pharma Inc. updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit Description 99.1 Corporate Presentation, dated April 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ACASTI PHARMA INC. Date: April 1, 2024 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing